MEDPLUSMedplus Health Services Ltd.

₹775-1.17%

Market Cap

₹9,393.49 Cr

Stock P/E

52.68

ROCE

18.22%

ROE

9.21%

Book Value

₹146.70

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Significant near-term store-network expansion with substantial openings and net additions.
•
Diagnostics business shows improving profitability with meaningful scale.

NEGATIVES

•
Growth momentum is weak with SSG negative, signaling continued demand- and execution-related headwinds.
•
Near-term margin risk linked to private-label mix and promotional incentives; some quarters show pressure.

Peers Summary

Sector Leader

Medplus Health Services Ltd. shows strong revenue growth and efficiency metrics compared to its peers, but its high PE ratio indicates it may be overvalued. Companies like Cipla and Dr. Reddy's Laboratories stand out for their profitability and reasonable valuation, while Divi's Laboratories faces challenges due to poor revenue growth.

Key Points

• Medplus has the highest revenue growth YoY among peers at 23.42%.
• Cipla and Dr. Reddy's have the best profitability metrics, with ROE above 16%.
• Divi's Laboratories is facing declining revenue growth and EPS, indicating potential weaknesses.
• Cipla and Dr. Reddy's are attractive value picks due to low PE ratios and strong earnings performance.

Top Performers

Cipla Ltd.

Strong profitability metrics with a low PE ratio (23.73), indicating good value.

Dr. Reddy's Laboratories Ltd.

High ROE and low PE (15.50), making it financially attractive.

Mankind Pharma Ltd.

Good growth trajectory with strong ROE and low debt levels.

Explore

Watchlists

Command Palette